Grant of Purchase Rights and Verici update
("RenalytixAI", the "Company")
Grant of Purchase Rights under the 2020 Employee Share Purchase Plan
and
Verici update
The Purchase Rights are in the form of a right to acquire the Company's American Depositary Shares (each representing two ordinary shares in the capital of the Company) ("ADSs") on
The 2020 ESPP was approved by shareholders at the general meeting of the Company held on
Verici update
The Company announced on
Additional information relating to the shares in Verici can be found in the announcement made by RenalytixAI on
For further information, please contact:
|
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: 020 7496 3000 |
|
|
|
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
a)
|
|
|
||||
2
|
Reason for the notification
|
|||||
a)
|
Position/status
|
Chief Financial Officer (PDMR) |
||||
b)
|
Initial notification /Amendment
|
Initial notification |
||||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
a)
|
|
|
||||
b)
|
LEI
|
213800NTOH3FK3WER551 |
||||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
) a)
|
Description of the financial instrument, type of instrument |
Purchase rights over American Depositary Shares each representing two ordinary shares of |
||||
|
|
|||||
Identification code |
GB00BYWL4Y04 |
|||||
|
|
|||||
b)
|
Nature of the transaction
|
Grant of purchase rights |
||||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
Unknown |
Unknown |
|
|
|
|
|
|
|
||
d)
|
Aggregated information |
|
||||
|
|
|||||
- Aggregated volume |
Unknown |
|||||
|
|
|||||
- Price |
Unknown |
|||||
|
|
|||||
e)
|
Date of the transaction
|
|
||||
f) |
Place of the transaction |
Outside a trading venue |
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, clinical care, patient stratification for drug clinical trials and drug target discovery. For more information, visit www.renalytixai.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the